Steroid-Refractory Immune Enteritis: Two Biologics With No Head-to-Head Trial Between Them
A single patient, five days into high-dose steroids with no real improvement, whose melanoma is responding to the exact drug now attacking her gut. The disagreement is between two biologics that have never been tested against each other in a real trial.
Diane W., a 66-year-old woman, still meets the same three friends for coffee every Sunday morning she's kept for two decades, a routine that got her through the eighteen months since her melanoma diagnosis more than almost anything else has. She has approached treatment with the same clinical precision she once brought to thirty-one years on medical-surgical floors as a nurse, tracking every lab value from her pembrolizumab infusions in a notebook she still keeps by habit. That melanoma has responded well — her most recent scans showed continued regression of both known metastases — but three weeks ago she developed grade 3 diarrhea, eight to ten watery stools daily with abdominal cramping, and colonoscopy with biopsy confirmed immune checkpoint inhibitor-induced enteritis, with active inflammation extending into the distal small bowel on capsule endoscopy performed after the colonoscopy's own findings didn't fully explain her symptom severity. Pembrolizumab was held immediately and high-dose IV corticosteroids started five days ago.
Her diarrhea has not meaningfully improved on steroids, meeting the threshold for steroid-refractory disease that calls for biologic escalation — and here the evidence gets genuinely harder to read than a single confident recommendation would suggest. No randomized comparison of infliximab against vedolizumab has yet reported for this indication — one is enrolling, but its published interim data runs to a handful of patients per arm — so the most recent pooled analysis is what the decision rests on: Shambhavi and colleagues, six retrospective cohorts totaling 645 patients, found vedolizumab associated with a real, statistically significant lower recurrence rate than infliximab (odds ratio 0.29, 95% CI 0.15–0.54) and meaningfully shorter total steroid exposure, but no significant difference in remission rates between the two drugs themselves — both achieve comparably high response, they differ mainly in what happens after. Vedolizumab's gut-selective mechanism, unlike infliximab's broader TNF blockade, does not add further systemic immune suppression on top of an immune system that is, at the same time, actively working against her melanoma — a real and specific consideration given her cancer's own current trajectory, though real-world data also suggests vedolizumab tends to reach full effect somewhat more slowly than infliximab in practice.
GI/oncology joint clinic, steroid-refractory enteritis
I want to escalate to infliximab. It’s the agent with the longer accumulated track record specifically in immune-mediated enterocolitis, and in some retrospective comparisons it reaches steroid-taper completion faster. No trial has definitively separated the two drugs, and I think a longer real-world history in exactly this indication is a real, if imperfect, form of evidence worth weighting.
I’d go with vedolizumab. Shambhavi's pooled analysis — six cohorts, 645 patients — found a real, statistically significant lower recurrence rate with vedolizumab, odds ratio 0.29, and meaningfully shorter total steroid exposure, with no significant difference in remission rates between the two drugs. And I want to bring in something specific to her: vedolizumab’s gut selectivity means we’re not adding further systemic immune suppression on top of an immune system that is, right now, actively controlling her melanoma. Infliximab’s broader TNF blockade doesn’t carry that same distinction.
I take the track-record point seriously, but "used longer" and "works better for her specific situation" aren’t the same claim — and the newest comparative data we actually have points toward the drug that doesn’t touch her systemic antitumor immunity.
I want to name something both of you are working around: the same literature shows comparably high remission rates for both drugs. The place they actually differ is what happens after remission and how fast they get her there — and real-world data does suggest vedolizumab tends to reach full effect somewhat more slowly than infliximab in practice, even though it holds better once achieved.
Given how refractory she already is at day five, I don’t think we can afford to spend more time deliberating between two drugs with comparable remission rates. I’d favor vedolizumab for the reasons the oncologist gave — it’s a real, specific consideration given her active melanoma treatment — but I want us to set an explicit, short reassessment window given the speed concern, rather than assuming vedolizumab’s superior recurrence profile guarantees it will also work fast enough for how sick she is right now.
Agreed: vedolizumab starts today, with steroids continued and a hard 5-7 day reassessment window set in advance given vedolizumab’s typically slower onset; infliximab named explicitly as the fallback if that window shows no meaningful improvement, rather than left as an unstated option.
Not agreed: the gastroenterologist remains genuinely unpersuaded that vedolizumab is the better first choice for a patient already this refractory at day five, given infliximab’s faster reported onset in some series — a position noted rather than overridden, with the short reassessment window serving as the group’s compromise rather than a resolution of the underlying disagreement.